Residence in Skilled Nursing Facilities Is Associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae

Infection Control and Hospital Epidemiology

Volumn 36, Issue 8, 2015, Pages 942-948

  Van Duin, David ^a   Cober, Eric ^b   Richter, Sandra S ^c   Perez, Federico ^d,e   Kalayjian, Robert C ^f   Salata, Robert A ^e   Evans, Scott ^g   Fowler, Vance G ^h   Bonomo, Robert A ^d,e,i   Kaye, Keith S ^j  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Department of Infectious Diseases ^*  (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Research Service   (United States)

^e Div of Infectious Diseases   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

^g CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NURSING HOME; NURSING HOME PATIENT; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; RISK FACTOR; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; RISK FACTORS; SKILLED NURSING FACILITIES; TIME FACTORS;

EID: 84994060942     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2015.118     Document Type: Article

References (26)

1. Perez F, van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med 2013;80:225-233.
2. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785-796.
3. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenemresistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013;75:115-120.
4. Flamm RK, Farrell DJ, Sader HS, Jones RN. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 2014;69:1589-1598.
5. Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD Study, 2011-2012. Antimicrob Agents Chemother 2014;58:2554-2563.
6. Mathers AJ, Cox HL, Kitchel B, et al. Molecular dissection of an outbreak of carbapenem-resistant enterobacteriaceae reveals Intergenus KPC carbapenemase transmission through a promiscuous plasmid. MBio 2011;2:e00204-e00211.
7. Van Duin D, Cober E, Richter S, et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014;20: O1117-O1120.
8. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014;58:4035-4041.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute, 2014:34.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72.
11. American Thoracic Society. and Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
12. CDC/NHSN surveillance definitions for specific types of infections. Centers for Disease Control and Prevention website. http://www. cdc.gov/nhsn. Published 2014. Accessed May 2014.
13. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999;11:7-12.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
15. Nigo M, Cevallos CS, Woods K, et al. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013;57:5743-5746.
16. Prabaker K, Lin MY, McNally M, et al. Transfer from highacuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae: a multihospital study. Infect Control Hosp Epidemiol 2012;33:1193-1199.
17. Marchaim D, Chopra T, Bogan C, et al. The burden of multidrugresistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. Am J Infect Control 2012;40:760-765.
18. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010;31:620-626.
19. Adler A, Hussein O, Ben-David D, et al. Persistence of Klebsiella pneumoniae ST258 as the predominant clone of carbapenemaseproducing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008-13. J Antimicrob Chemother 2015;70:89-92.
20. Nursing homes and assisted living (long-term care facilities [LTCFs]). Centers for Disease Control and Prevention website. http://www.cdc.gov/longtermcare/. Published 2014. Accessed November 13, 2014.
21. Daneman N, Gruneir A, Bronskill SE, et al. Prolonged antibiotic treatment in long-term care: role of the prescriber. JAMA Intern Med 2013;173:673-682.
22. Daneman N, Gruneir A, Newman A, et al. Antibiotic use in long-term care facilities. J Antimicrob Chemother 2011;66: 2856-2863.
23. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-844.
24. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-950.
25. Winkler ML, Papp-Wallace KM, Hujer AM, et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2015;59: 1020-1029.
26. McKinnell JA, Kunz DF, Chamot E, et al. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol 2012;33:718-724.